Pharma has value names, but it's not a top pick for 2025, says BMO's Evan Siegerman
0
0
23/12/24
Dans
Amérique du Nord / États-Unis
Evan Siegerman, BMO biotech analyst, joins 'Power Lunch' to discuss the big winners in the pharmaceutical space in 2025.
Montre plus
0 commentaires
sort Trier par
